Inpatient Management of Opioid Use Disorder: A Review for Hospitalists

Jesse Theisen-Toupal, MD1-3*, Matthew V. Ronan, MD4,5, Amber Moore, MD, MPH5,6, Elana S. Rosenthal, MD7

1Medical Service, VA Medical Center, Washington, District of Columbia; 2George Washington University School of Medicine and Health Sciences, Washington, District of Columbia; 3Uniformed Services University of the Health Sciences, Bethesda, Maryland; 4Medical Service, VA Medical Center, West Roxbury, Massachusetts; 5Harvard Medical School, Boston, Massachusetts; 6Division of General Medicine and Primary Care, Beth Israel Deaconess Medical Center, Boston, Massachusetts; 7Institute of Human Virology, Division of Infectious Diseases, University of Maryland School of Medicine, Baltimore, Maryland.

The United States is experiencing an epidemic of nonmedical opioid use and opioid overdose-related deaths. As a result, there have been a number of public health interventions aimed at addressing this epidemic. However, these interventions fail to address care of individuals with opioid use disorder during hospitalizations and, therefore, miss a key opportunity for intervention. The role of hospitalists in managing hospitalized patients with opioid use disorder is not established. In this review, we discuss the inpatient management of individuals with opioid use disorder, including the treatment of withdrawal, benefits of medication-assisted treatment, and application of harm-reduction strategies. Journal of Hospital Medicine 2017;12:369-374. © 2017 Society of Hospital Medicine

Revised: January 28, 2016; Accepted: September 25, 2016
2017 Society of Hospital Medicine DOI 10.12788/jhm.2731
TABLE 1. Treatment Options for Opioid Withdrawal\(^4,17-20\)

Opioid substitution treatment

**Methadone**
- Initial dose: 10 to 20 mg of oral, or 10 mg of intramuscular, methadone
- Reassess and re-dose: reassess the patient every 2 to 4 hours; if the patient has withdrawal symptoms, give an additional 10 mg of oral methadone; if the symptoms are controlled or the patient is somnolent, do not give additional doses; the maximum first day dose of oral methadone is 40 mg.
- Taper: reduce the daily dose by 10% to 20% daily; the taper duration will last approximately 10 to 14 days.
- Monitoring: EKG before and after methadone administration
- Selected adverse effects: sedation, constipation, prolonged QTc, torsades de pointes

**Buprenorphine\(^a\)**
- Initial dose: 4 mg of sublingual buprenorphine
- Reassess and re-dose: reassess the patient in 2 to 4 hours; if the patient has withdrawal symptoms, give an additional 4 mg of sublingual buprenorphine; if the symptoms are controlled or the patient is somnolent, do not give additional doses; the day 1 maximum dose is 8 mg of sublingual buprenorphine; titrate as needed for withdrawal symptoms over the next 3 days; day 2 maximum dose is 12 mg of sublingual buprenorphine; day 3 maximum dose is 16 mg of sublingual buprenorphine.
- Taper: reduce the daily dose by 1 to 2 mg daily; the taper duration will last approximately 10 to 14 days.
- Selected adverse effects: sedation, constipation, insomnia

**Alpha\(_2\)-adrenergic agonist treatment**

**Clonidine**
- Initial dose: 0.1 to 0.3 mg of oral clonidine
- Reassess and re-dose: reassess the patient every 2 to 4 hours; if the patient has withdrawal symptoms, give an additional 0.1 to 0.3 mg of oral clonidine; if the patient is hypotensive, somnolent, or with other signs of clonidine toxicity, do not give additional doses; typical doses are 0.1 to 0.3 mg every 6 to 8 hours.
- Taper: reduce the daily dose of clonidine by 0.1 to 0.2 mg per day; the taper duration will last approximately 10 to 14 days.
- Selected adverse effects: sedation, headache, hypotension, bradycardia

**Adjunctive medications**
- Diarrhea: anti-motility agents such as loperamide
- Nausea/vomiting: anti-emetics such as ondansetron
- Abdominal cramps: antispasmodics such as dicyclomine
- Muscle and joint aches: analgesics such as acetaminophen or ibuprofen
- Anxiety, irritability, and restlessness: anxiolytics such as lorazepam
- Muscle spasms: antispasmodics such as cyclobenzaprine or baclofen
- Abdominal cramps: antispasmodics such as dicyclomine
- Anxiolytics such as lorazepam
- Insomnia: sleeping medication such as trazodone

\(^a\)Buprenorphine-naloxone can be used instead of buprenorphine; buprenorphine can result in opioid withdrawal and should be used only in patients with clear evidence of opioid withdrawal.

**NOTE:** Abbreviation: EKG, electrocardiogram

30% will be discharged against medical advice.\(^{15,16}\) In hospitalizations when patients are administered methadone for management of withdrawal, there is a significant reduction in discharges against medical advice.\(^{16}\) This may suggest that treatment of withdrawal has the added benefit of preventing discharges against medical advice, and the authors postulate that treatment may decrease surreptitious drug use during hospitalizations, although this has not been studied.

There are 2 approaches to treating opioid withdrawal—opioid substitution treatment and alpha\(_2\)-adrenergic agonist treatment (Table 1).\(^{4,17-20}\) Of note, opioid substitution treatment, especially when using buprenorphine, should be started only when a patient has at least mild withdrawal symptoms.\(^20\)

An important exception to the treatment approach listed in Table 1 occurs when a patient is already taking methadone or buprenorphine maintenance therapy. In this circumstance, the outpatient dose should be continued after confirmation of dose and timing of last administration with outpatient clinicians. It is important that clear communication with the patient’s addiction clinician occurs at admission and discharge to prevent an inadvertently duplicated, or missed, dose.

Factors to consider when selecting a withdrawal treatment regimen include comorbidities, anticipated length of stay, anticipated discharge setting, medications, interest in long-term addiction treatment, and other patient-specific factors. In general, treatment with methadone or buprenorphine is preferred, because they are better tolerated and may be more effective than clonidine.\(^{21,22}\) The selection of methadone or buprenorphine is often based on physician or patient preference, presence of contraindications, or formulary restrictions, as they have similar efficacy in the treatment of opioid withdrawal.\(^23\) In cases where opioid replacement therapy is contraindicated, such as in an individual who has received naltrexone, clonidine should be used.\(^{24}\)

Methadone and buprenorphine are controlled substances that can be prescribed only in outpatients by certified clinicians. Therefore, hospitalists are prohibited from prescribing these medications at discharge for the treatment of OUD. However, inpatient clinicians are exempt from these regulations and may provide both medications for maintenance and withdrawal treatment in the inpatient setting.

As such, while a 10 to 14-day taper may be optimal in preventing relapse and minimizing withdrawal, patients are often medically ready to leave the hospital before their taper is completed. In these cases, a rapid taper over 3 to 5 days can be considered. The disadvantage of a rapid taper is the potential for recrudescence of withdrawal symptoms after discharge. Individuals who do not tolerate a rapid taper should be treated with a slower taper, or transitioned to a clonidine taper.

Many hospitals have protocols to help guide the inpatient management of withdrawal, and in many cases, subspecialist consultation is not necessary. However, the authors recommend involvement of an addiction specialist for patients in whom management of withdrawal may be complicated. Further, we strongly encourage hospitalists to be involved in creation and maintenance of withdrawal treatment protocols.

**Medication-Assisted Treatment**

It is important to recognize that treatment of withdrawal is not adequate to prevent long-term opioid misuse.\(^25\) The optimal long-term management of OUD includes the use of medication-assisted treatment (MAT). The initiation and titration of MAT should always be done in conjunction with an addiction specialist or buprenorphine-waivered physician who will ensure continuation of MAT as an outpatient. This means that, while hospitalists may be critical in facilitating linkage to MAT, in general, they will not have a significant role in the long-term management of OUD. However, hos-
pitalists should be knowledgeable about MAT because it is relatively common and can complicate hospitalizations.

There are two types of MAT: opioid-agonist treatment (OAT) and opioid-antagonist treatment. Opioid-agonist treatment involves the use of methadone, a long-acting opioid agonist, or buprenorphine, a long-acting partial opioid agonist. These medications decrease the amount and severity of cravings and limit the euphoric effects of subsequent opioid use. Compared to abstinence-based treatment, OAT has been associated with increased retention in addiction treatment and employment, and reductions in incarceration, human immunodeficiency virus transmission, illicit drug use, opioid-overdose events, and mortality. An alternative to OAT is naltrexone, an opioid antagonist. Naltrexone for OUD is administered as a monthly depot injection that prevents the user from experiencing opioid intoxication or dependence, and is associated with sustained abstinence. The authors strongly recommend that hospitalists discuss the benefits of MAT with hospitalized individuals with OUD. In addition, when appropriate, patients should receive consultation with, or referral to, an addiction specialist.

**Adverse Effects of Methadone, Buprenorphine, and Naltrexone**

The benefits of MAT are substantial, but there are adverse effects, potential drug-to-drug interactions, and patient-specific characteristics that may impact the inpatient management of individuals on MAT. Selected adverse effects of OAT are listed in Table 1. The adverse effects of naltrexone include nausea, vomiting, and transaminitis. It should also be noted that the initiation of buprenorphine and naltrexone may induce opioid withdrawal when administered to an opioid-dependent patient with recent opioid use. To avoid precipitating withdrawal, buprenorphine should be used only in individuals who have at least mild withdrawal symptoms or have completed detoxification, and naltrexone should be used only in patients who have abstained from opioids for at least 7 to 10 days.

Opioid-agonist treatments are primarily metabolized by the cytochrome P450 3A4 isoenzyme system. Medications that inhibit cytochrome P450 3A4 metabolism such as fluconazole can result in OAT toxicity, while medications that induce cytochrome P450 3A4 metabolism such as dexamethasone can lead to withdrawal symptoms. If these interactions are unavoidable, the dose of methadone or buprenorphine should be adjusted to prevent toxicity or withdrawal symptoms. The major drug interaction with naltrexone is ineffective analgesia from opioids.

Another major concern with MAT is the risk of overdose-related deaths. As an opioid agonist, large doses of methadone can result in respiratory depression, while buprenorphine alone, due to its partial agonist effect, is unlikely to result in respiratory depression. When methadone or buprenorphine are taken with other substances that cause respiratory depression, such as benzodiazepines or alcohol, the risk of respiratory depression and overdose is significantly increased. Overdose-related death with naltrexone usually occurs after the medication has metabolized and results from a loss of opioid tolerance.

**Special Populations**

Medication-assisted treatment in individuals with acute pain. Maintenance treatment with OAT does not provide sufficient analgesia to treat episodes of acute pain. In patients on methadone maintenance, the maintenance dose should be continued and adjunctive analgesia should be provided with nonopioid analgesics or short-acting opioids. The management of acute pain in individuals on buprenorphine maintenance is more complicated since buprenorphine is a partial opioid agonist with high affinity to the opioid receptor, which limits the impact of adjunctive opioids. The options for analgesia in buprenorphine maintenance treatment include 1) continuing daily dosing of buprenorphine and providing nonopioid or opioid analgesics, 2) dividing buprenorphine dosing into a 3 or 4 times a day medication, 3) discontinuing buprenorphine and treating with opioid analgesics, 4) discontinuing buprenorphine and starting methadone with nonopioid or opioid analgesics. In cases where buprenorphine is discontinued, it should be restarted before discharge upon resolution of the acute pain episode. An individual with acute pain on naltrexone may require nonopioid analgesia or regional blocks. In these patients, adequate pain control may be challenging and require the consultation of an acute pain specialist.

**Pregnant or breastfeeding individuals.** Opioid misuse puts the individual and fetus at risk of complications, and abrupt discontinuation can cause preterm labor, fetal distress, or fetal demise. The current standard is to initiate methadone in consultation with an addiction specialist. There is evidence that buprenorphine can be used during pregnancy; however, buprenorphine-naloxone is discouraged. Of note, use of OAT in pregnancy can result in neonatal abstinence syndrome, an expected complication that can be managed by a pediatrician.

Methadone and buprenorphine can be found in low concentrations in breast milk. However, according to the Academy of Breastfeeding Medicine’s clinical guidelines, women on stable doses of methadone and buprenorphine should be encouraged to breastfeed. Naltrexone enters breast milk and has potential adverse effects for the newborn. Either the mother should discontinue naltrexone or should not breastfeed.

**Treatment of polysubstance misuse.** Individuals with OUD may also misuse other substances. The concomitant use of opioids and other central nervous system depressants, such as alcohol and benzodiazepines, is especially worrisome as they can potentiate respiratory depression. The presence of polysubstance misuse does not preclude the use of MAT for the treatment of OUD. In those with comorbid alcohol use disorder, the use of naltrexone may be appealing as it can treat both alcohol use disorder and OUD. Given the complexities of managing polysubstance misuse, addiction...
specialists should be involved in the care of these patients. In addition, patients should be educated on the risks of poly-substance misuse, especially when it involves 2 central nervous system depressants.

Comorbid medical disease. In general, medical comorbidities do not significantly affect the treatment of OUD; however, dysfunction of certain organ systems may necessitate a dose reduction or discontinuation of MAT. Severe liver disease may result in decreased hepatic metabolism of OAT. Prolonged QTc, or history of arrhythmia, may preclude the use of methadone. In addition, chronic hypercapnic respiratory failure or severe asthma may be contraindications for the use of methadone in an unmonitored setting. Kidney failure is not known to be a contraindication to MAT, and there is no consensus on the need for dose reduction of MAT with decreasing glomerular filtration rate; however, some authors recommend a 25% to 50% dose reduction of methadone when the glomerular filtration rate is less than 10 milliliters per minute. There is no such recommendation with buprenorphine, although it has not been adequately studied in individuals with renal failure. Close monitoring for evidence of toxicity is prudent in individuals on MAT with acute or chronic renal failure.

Rural or resource-limited areas. There is a significant shortage of addiction treatment options in many regions of the United States. As of 2012, there were an estimated 2.3 million individuals with OUD; however, more than 1 million of these individuals do not have access to treatment. As a result, many addiction treatment programs have wait lists that can last months or even years. These shortages are especially apparent in rural areas, where individuals with OUD are particularly reliant upon buprenorphine treatment because of prohibitive travel times to urban-based programs. To address this problem, new models of care delivery are being developed, including models incorporating telemedicine to support rural primary care management of OUD.

The Future of Medication-Assisted Treatment
Currently, MAT is initiated and managed by outpatient addiction specialists. However, evidence supports initiation of MAT as an inpatient. A recent study compared inpatient buprenorphine detoxification to inpatient buprenorphine induction, dose stabilization, and postdischarge linkage-of-care to outpatient opioid treatment clinics. Patients who received inpatient buprenorphine initiation and linkage-of-care had improved buprenorphine treatment retention and reported less illicit opioid use. The development of partnerships between hospitals, inpatient clinicians, and outpatient addiction specialists is essential and could lead to significant advances in treating hospitalized patients with OUD.

The initiation of MAT in hospitalized patients with immediate linkage-of-care shows great promise; however, at this point, the initiation of MAT should be done only in conjunction with addiction specialists in patients with confirmed outpatient follow-up. In cases where inpatient MAT initiation is pursued, education of staff including nurses and pharmacists is essential.

### TABLE 2. Harm Reduction Strategies

<table>
<thead>
<tr>
<th>Safer injection education</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Recognize the signs of opioid overdose.</td>
</tr>
<tr>
<td>• Deep sleeping that does not respond to shaking or attempts to wake up</td>
</tr>
<tr>
<td>• Seizuring, gurgling, or choking</td>
</tr>
<tr>
<td>• No breathing or slow breathing (less than 1 breath per 5 seconds)</td>
</tr>
<tr>
<td>• Blue or gray lips or fingernails</td>
</tr>
<tr>
<td>• Pale, clammy skin</td>
</tr>
<tr>
<td>2. Contact emergency medical services. Tell emergency medical services that the person has overdosed on opioids. Alert emergency medical services if the person is not breathing</td>
</tr>
<tr>
<td>3. Administer naloxone. Naloxone can be prescribed in different preparations (intramuscular and intranasal).</td>
</tr>
<tr>
<td>• Intramuscular naloxone, 0.4 mg (1 mL)</td>
</tr>
<tr>
<td>○ Remove cap from naloxone vial, insert needle through rubber plug, pull 1 mL of naloxone into syringe, inject into a large muscle (upper arm, upper thigh, or buttocks), and safely dispose of syringe.</td>
</tr>
<tr>
<td>• Intramuscular auto-injector naloxone (Ezi-Jet®), 0.4 mg</td>
</tr>
<tr>
<td>○ Visual and voice instructions help prompt through injection process; remove auto-injector from outer case, pull red safety guard, place the black end against the middle of the outer thigh (all right to go through clothing), and hold firmly in place for 5 seconds. There will be a click and a hiss sound meaning that naloxone has been administered. The needle will automatically retract into the case after use.</td>
</tr>
<tr>
<td>• Intranasal naloxone, 2 mg</td>
</tr>
<tr>
<td>○ Pull off both end caps of syringe barrel, screw atomizer onto tip of syringe barrel, pull off end cap of naloxone cartridge and screw naloxone cartridge into syringe barrel, and insert into nose; push naloxone cartridge and empty half of cartridge into one nostril, then empty the rest of cartridge into the other nostril.</td>
</tr>
<tr>
<td>• Intranasal naloxone (Narcar®), 4 mg</td>
</tr>
<tr>
<td>○ Remove nasal spray from package, place tip into nostril, and press plunger to release full dose into nostril.</td>
</tr>
<tr>
<td>4. Perform cardiopulmonary resuscitation and/or rescue breathing if needed.</td>
</tr>
<tr>
<td>5. Stay with the person until emergency medical services arrive.</td>
</tr>
</tbody>
</table>

*After 3 to 5 minutes, if there is no response to naloxone, another dose of naloxone can be administered. Naloxone should be kept on the person at all times. It should be stored at room temperature to avoid extreme temperatures (heat or cold) and light.

Harm Reduction Interventions
Ideally, management of OUD results in abstinence from opioid misuse; however, some individuals are not ready for treatment or, despite MAT, have relapses of opioid misuse.
Given this, a secondary goal in the management of OUD is the reduction of harm that can result from opioid misuse. Many individuals inject opioids, which is associated with increased rates of viral and bacterial infections secondary to nonsterile injection practices. Educating patients on sterile injection methods (Table 2), including the importance of sterile-injecting equipment and water, and cleaning the skin prior to injection, may mitigate the risk of infections and should be provided for all hospitalized people who inject drugs. Syringe-exchange programs provide sterile-injecting equipment in exchange for used needles, with a goal of increasing access to sterile supplies and removing contaminated syringes from circulation. While controversial, these programs may reduce the incidence of human immunodeficiency virus, hepatitis C virus, and hepatitis B virus.

In addition, syringe-exchange programs often provide addiction treatment referrals, counseling, testing, and prevention education for human immunodeficiency virus, hepatitis C virus, and sexually transmitted infections. In the United States, there are 226 programs in 33 states (see https://nasen.org/directory for a list of programs and locations. Inpatient clinicians should provide a list of local resources including syringe-exchange programs at the time of discharge for any individuals who inject drugs. In addition, individuals with OUD are at increased risk for overdose, especially in the postdischarge setting due to decreased opioid tolerance. To address this troubling epidemic, opioid overdose education and naloxone distribution has been championed to educate patients at risk of opioid overdose and potential first responders on how to counteract an overdose by using naloxone, an opioid antagonist (see Table 2 for more information on opioid overdose education). The use of opioid overdose education and naloxone distribution has been observed to reduce opioid overdose-related death rates.

Hospitalists should provide opioid overdose education and naloxone to all individuals at risk of opioid overdose (including those with OUD), as well as potential first responders where the law allows (more information including individual state laws can be found at http://prescribetoprevent.org).

Considerations at Discharge

There are a number of considerations for the hospitalist at discharge (see Table 3 for a recommended discharge checklist). In addition, it is important to appreciate, and minimize, the ways that hospitalists contribute to the opioid epidemic. For instance, prescribing opioids at discharge in opioid-naïve patients increases the risk of chronic opioid use. It is also essential to recognize that increased doses of opioids are associated with increased rates of opioid overdose-related deaths. As such, hospitalists should maximize the use of nonopioid analgesics, prescribe opioids only when necessary, use the smallest effective dose of opioids, limit the number of opioid pills distributed to patients, and check prescription-monitoring programs for evidence of misuse.

CONCLUSION

Hospitalization serves as an important opportunity to address addiction in individuals with OUD. In addressing addiction, hospitalists should identify and intervene on psychosocial and mental health barriers, treat opioid withdrawal, and propagate harm reduction strategies. In addition, there is a growing role for hospitalists to be involved in the initiation of MAT and linkage-of-care to outpatient addiction treatment. If hospitalists become leaders in the inpatient management of OUD, they will significantly improve the care provided to this vulnerable patient population.

Disclosure: The authors report no financial conflicts of interest.

References
